Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During the quarter,

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ($CVS) and Cigna

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide range of health solutions in the United States. With offerings that span pharmacy benefit management,

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and

The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, CVS's Health Care Benefits segment operates as one of the largest diversified health care benefits providers, serving more than 35 million people. This segment accounts for approximately 30% of the consolidated revenue.

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by a high estimate of $82.00 and a low estimate of $58.00. This current average has decreased by 0.93% from the previous average price target of $68.71.

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $65.0 for CVS Health over the last 3 months.

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.

CVS Health Corporation (NYSE ... owning a healthcare benefits business (Aetna), a pharmacy-benefits manager (Caremark), an in-home evaluation business (Signify Health) and in-home primary care ...

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months critical of pharmacy benefit managers.